Berry Genomics Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Chengdu Beirui Hekang Gene Technology Co., Ltd. was established in May 2010 and listed on the A-share main board in 2017 (stock code: 000710). The company is committed to the comprehensive transformation of gene sequencing technology into clinical applications, focusing on fields such as reproductive health, genetic disease detection, tumor detection, and technological services. It has established a research and development, production, marketing, sales, and customer service system based on international standards. The company is headquartered in Beijing and has established medical laboratory facilities in Beijing, Shanghai, Chongqing, Qingdao, Fuzhou, and Hong Kong. It also has a production base for reagents and gene sequencers in Hangzhou. The company has built a digital life industry park in Fuzhou with a scale of over 230000 square meters, which is one of the few gene technology industry clusters in China that integrates the entire process of research and development, testing, production, and treatment. In the field of reproductive health, in 2011, Berry Gene launched the "Bebian" non-invasive DNA prenatal testing service on the market and continued to contribute to the birth defect prevention system, laying out a three-level prevention strategy for pre pregnancy, prenatal, and newborn babies. So far, a total of over 5 million genetic testing services have been provided, reducing the economic burden on society and families by tens of billions of yuan. In the field of genetic disease detection, Bairui Gene focuses on creating a professional, efficient, and high-quality comprehensive diagnostic platform for genetic diseases. Currently, with WES and CNV-seq technology as the core, it provides multiple detection combinations for clinical use, playing an important role in genetic disease detection in children and adults. In the field of tumor detection, a joint subsidiary of Rui Gene focuses on gene testing throughout the entire course of cancer. In addition to developing multiple mid to late stage tumor detection products, in the early screening of liver cancer, we have launched a clinical level product, Laisining, which has been validated through large-scale prospective follow-up cohort studies. The company's cooperation and service network covers over 700 tertiary hospitals across the country, providing valuable tumor gene testing services to hundreds of thousands of cancer patients, gradually achieving a strategic layout from advanced detection to very early detection. In the field of technology services, the company maintains highly close strategic cooperation with sequencing platform suppliers Illumina, PacBio, BioNano, and Oxford Nanopore, and has international mainstream gene sequencing platforms. We have established over 40 sub product types for scientific research services, providing comprehensive and accurate analytical services for life science research. At present, the company's business covers more than 30 provinces, municipalities, autonomous regions, Hong Kong, Macao, and Taiwan in China, as well as overseas markets such as Southeast Asia, the Middle East, and Australia. More than 4000 medical institutions, research institutions, higher education institutions, and enterprises have used the overall gene sequencing solution of Berry Gene. |
| Headquarter | Chengdu |
| Establish Date | 4/14/1997 |
| Listed Code | 000710.SZ |
| Listed Date | 4/22/1997 |
| Chairman | Gao Yang. |
| CEO | Gao Yang. |
| Website | www.berrygenomics.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
